Dr. Lugui Qiu: Progress Flourishes with a Precision-Based Lymphoma Diagnosis and Treatment System

Dr. Lugui Qiu: Progress Flourishes with a Precision-Based Lymphoma Diagnosis and Treatment System

Lymphoma is a common malignant disease of the lymphatic system that poses a significant threat to public health. China faces a rapidly increasing burden of lymphatic tumors. The GBD 2019 study shows that China accounts for 10.8% of the world's new cases of Hodgkin lymphoma and 9.8% of the deaths, as well as 20.1% of the new cases and 17.4% of the deaths from non-Hodgkin lymphoma. Therefore, improving lymphoma diagnosis and treatment levels is a critical challenge in China. To gain a deeper understanding of the current status and progress of lymphoma diagnosis and treatment in China, Hematology Frontier interviewed Dr. Luguo Qiu, Director of the Lymphoma Diagnosis and Treatment Center at the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences , for an in-depth analysis of this topic.
World Leukemia Day: Building a Health Defense, Lighting the Flame of Life

World Leukemia Day: Building a Health Defense, Lighting the Flame of Life

September 4 marks "World Leukemia Day," an initiative launched by the Acute Leukemia Advocates Network, CLL Advocates Network, CML Advocates Network, and Leukaemia Care. The day is dedicated to raising global awareness about leukemia, promoting efforts in prevention, diagnosis, treatment, and recovery. Leukemia, often called "blood cancer," is a complex disease with high treatment costs and the risk of relapse, placing a heavy burden on many families. However, through awareness and action on this day, we aim to break the silence and helplessness, and collectively ignite a beacon of hope for leukemia patients.
Dr. Jin Gu: Significant Benefits of Combined Pelvic Organ Resection for High-Risk Locally Advanced Rectal Cancer | Guangzhou Colorectal Cancer Summit

Dr. Jin Gu: Significant Benefits of Combined Pelvic Organ Resection for High-Risk Locally Advanced Rectal Cancer | Guangzhou Colorectal Cancer Summit

From August 5th to 10th, 2024, the Guangzhou Colorectal Cancer Summit Forum and the 22nd Guangdong Provincial Colorectal Cancer Academic Conference were held in Guangzhou. During the event, Dr. Jin Gu from Peking University Shougang Hospital shared important insights and conclusions from his center’s experience with combined pelvic organ resection surgery for refractory rectal cancer. After the conference, we had the privilege of interviewing Professor Gu.
CSCO 2024丨Dr. Jiong Wu: INAVO120 Accelerates the Approval of New PI3Ki Inavolisib by CDE, Gene Testing Propels the Era of Precision Targeted Therapy

CSCO 2024丨Dr. Jiong Wu: INAVO120 Accelerates the Approval of New PI3Ki Inavolisib by CDE, Gene Testing Propels the Era of Precision Targeted Therapy

Hormone receptor-positive (HR+) breast cancer is the most common subtype of breast cancer, with approximately 40% of these patients harboring a PI3KCA mutation. This mutation is a primary cause of resistance to endocrine therapy and CDK4/6 inhibitors, leading to poorer prognosis for affected patients. At the 2024 CSCO Annual Meeting, Dr. Jiong Wu from Fudan University Shanghai Cancer Center, as the Leading PI, shared the latest findings from the Phase III INAVO120 study. The study demonstrated that the novel PI3K inhibitor, inavolisib, combined with CDK4/6 inhibitors and endocrine therapy, offers improved outcomes for these patients, providing a new treatment option. Based on these results, both the China National Medical Products Administration (CDE) and the U.S. FDA have granted fast-track review status to inavolisib, with hopes of delivering clinical benefits to patients soon. At the CSCO meeting, Oncology Frontier had the opportunity to interview Professor Wu, discussing key insights about inavolisib and providing clinical guidance on this emerging PI3K inhibitor.
National Healthy Lifestyle Promotion Month | Focusing on Breast Health: Authoritative Experts Discuss Breast Cancer Prevention and Treatment — Part2

National Healthy Lifestyle Promotion Month | Focusing on Breast Health: Authoritative Experts Discuss Breast Cancer Prevention and Treatment — Part2

Healthy living for all, together we uphold, and start a new chapter! September is the National Healthy Lifestyle Promotion Month. We focus on breast cancer, a significant disease threatening women's health, and have specially invited authoritative experts in the field of breast cancer from China to discuss the scientific prevention and treatment of breast cancer and the importance of a healthy lifestyle. The experts unanimously emphasize that facing the disease scientifically, actively preventing it, and treating it precisely are the keys to overcoming breast cancer. Let us join hands with a scientific attitude and firm belief to protect the beauty and dignity of life, and promote breast cancer prevention and treatment to new heights, contributing to the great goal of a Healthy China! We hope that through the experts' interpretations, we can not only enhance the public's understanding of breast cancer but also encourage patients and their families to actively participate in screening and advocate a healthy lifestyle, jointly promoting the development of breast cancer treatment towards more individualized and precise directions. Let us work together to light the way for breast cancer patients and create a healthy and bright future!